HIGHBRIDGE CAPITAL MANAGEMENT LLC - PARATEK PHARMACEUTICALS INC ownership

PARATEK PHARMACEUTICALS INC's ticker is and the CUSIP is 699374AB0. A total of 15 filers reported holding PARATEK PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.7%.

Quarter-by-quarter ownership
HIGHBRIDGE CAPITAL MANAGEMENT LLC ownership history of PARATEK PHARMACEUTICALS INC
ValueSharesWeighting
Q2 2023$34,151,524
+105270.2%
34,893,000
-13.3%
1.50%
+26.3%
Q1 2023$32,411
-3.8%
40,262,000
+11.1%
1.19%
+28.4%
Q4 2022$33,698
-99.9%
36,234,0000.0%0.93%
+103.5%
Q3 2022$32,473,000
-2.7%
36,234,0000.0%0.46%
-40.0%
Q2 2022$33,372,000
+4.5%
36,234,000
+1.7%
0.76%
+2.3%
Q1 2022$31,948,000
-1.2%
35,615,0000.0%0.74%
+5.2%
Q4 2021$32,321,000
-25.9%
35,615,000
-29.2%
0.71%
-38.8%
Q3 2021$43,615,000
-4.9%
50,277,000
+2.9%
1.15%
-9.3%
Q2 2021$45,855,000
+17.1%
48,847,000
+9.8%
1.27%
-18.5%
Q1 2021$39,153,000
+12.2%
44,492,000
+12.9%
1.56%
+16.7%
Q4 2020$34,911,000
+33.2%
39,392,000
+25.1%
1.34%
-5.4%
Q3 2020$26,208,000
+12.1%
31,481,000
+6.4%
1.41%
-29.0%
Q2 2020$23,376,000
-1.7%
29,590,000
-18.7%
1.99%
-21.9%
Q1 2020$23,790,000
-12.9%
36,390,000
-3.8%
2.55%
-15.7%
Q4 2019$27,328,000
+5.6%
37,825,0000.0%3.02%
-20.0%
Q3 2019$25,876,000
-11.3%
37,825,000
-8.5%
3.78%
+95.9%
Q2 2019$29,160,00041,325,0001.93%
Other shareholders
PARATEK PHARMACEUTICALS INC shareholders Q1 2020
NameSharesValueWeighting ↓
Athyrium Capital Management, LP 9,000,000$8,848,8435.74%
PenderFund Capital Management Ltd. 13,010,000$17,1875.34%
HIGHBRIDGE CAPITAL MANAGEMENT LLC 34,893,000$34,151,5241.50%
DeepCurrents Investment Group LLC 18,721,000$18,288,2260.72%
OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) 25,000,000$24,375,0000.51%
WATER ISLAND CAPITAL LLC 4,750,000$4,6860.44%
Westchester Capital Management, LLC 5,150,000$5,092,0280.16%
L & S Advisors Inc 935,000$915,4630.12%
Sculati Wealth Management, LLC 200,000$195,8210.10%
PALISADE CAPITAL MANAGEMENT, LP 3,368,000$3,298,0190.09%
View complete list of PARATEK PHARMACEUTICALS INC shareholders